Abstract
The purpose of this study was to correlate magnetic resonance imaging (MRI)-based lesion load assessment with clinical disability in early relapsing remitting multiple sclerosis (RRMS). Seventeen untreated patients (ten women, seven men; mean age 33.0 ± 7.9 years) with the initial diagnosis of RRMS were included for cross-sectional as well as longitudinal (24 months) clinical and MRI-based assessment in comparison with age-matched healthy controls. Conventional MR sequences, MR spectroscopy (MRS) and magnetisation transfer imaging (MTI) were performed at 1.5 T. Lesion number and volume, MRS and MTI measurements for lesions and normal appearing white matter (NAWM) were correlated to clinical scores [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC)] for monitoring disease course after treatment initiation (interferon β-1a). MTI and MRS detected changes [magnetisation transfer ratio (MTR), N-acetylaspartate (NAA)/creatine ratio] in NAWM over time. EDSS and lesional MTR increases correlated throughout the disease course. Average MTR of NAWM raised during the study (p < 0.05) and correlated to the MSFC score (r = 0.476, p < 0.001). At study termination, NAA/creatine ratio of NAWM correlated to the MSFC score (p < 0.05). MTI and MRS were useful for initial disease assessment in NAWM. MTI and MRS correlated with clinical scores, indicating potential for monitoring the disease course and gaining new insights into treatment-related effects.
Similar content being viewed by others
References
Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191
Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria". Ann Neurol 58(6):840–846
Filippi M, Rovaris M (2000) Magnetisation transfer imaging in multiple sclerosis. J Neurovirol 6(Suppl 2):S115–S1120
Tedeschi G, Bonavita S, McFarland HF et al (2002) Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44(1):37–42
Inglese M, Rovaris M, Bianchi S et al (2001) Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber’s hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 70(4):444–449
Narayana PA (2005) Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15(4 Suppl):46S–57S
Horsfield MA (2005) Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15(4 Suppl):58S–67S
Pascual-Lozano A, Martinez-Bisbal M, Bosca I et al (2006) Axonal damage and inflammation in early multiple sclerosis: effects of subcutaneously interferon-beta-1a treatment. Mult Scler 12:S186
Narayanan S, De Stefano N, Francis GS et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979–986
Sarchielli P, Presciutti O, Tarducci R et al (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64(2):204–212
Parry A, Corkill R, Blamire AM et al (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250(2):171–178
Richert ND, Ostuni JL, Bash CN et al (1998) Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 19(9):1705–1713
Kita M, Goodkin DE, Bacchetti P et al (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54(9):1741–1745
McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
Cutter GR, Baier ML, Rudick RA et al (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882
Rovaris M, Filippi M, Minicucci L et al (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21(2):402–408
Bakshi R, Thompson AJ, Rocca MA et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615–625
Zivadinov R, Stosic M, Cox J et al (2008) The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 255(0):61–74
Chen JT, Collins DL, Atkins HL et al (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63(2):254–262
Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45(1):37–45
Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68(22 Suppl 3):S72–S82
Giacomini PS, Arnold DL (2008) Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 21(3):272–277
Rovira A, Leon A (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol 67(3):409–414
Inglese M (2006) Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol 27(5):954–957
Khaleeli Z, Sastre-Garriga J, Ciccarelli O et al (2007) Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78(10):1076–1082
Wattjes MP, Harzheim M, Lutterbey GG et al (2008) Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 50(2):123–129
De Stefano N, Guidi L, Stromillo ML et al (2003) Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 24(Suppl 5):S283–S286
Filippi M, Rocca MA, Comi G (2003) The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2(6):337–346
Pascual AM, Martinez-Bisbal MC, Bosca I et al (2007) Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology 69(1):63–67
Inglese M, Li BS, Rusinek H et al (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50(1):190–195
Wattjes MP, Harzheim M, Lutterbey GG et al (2008) High field MR imaging and (1)H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 255(1):56–63
Rieckmann P (2005) Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 12(2):42–51
Neema M, Stankiewicz J, Arora A et al (2007) MRI in multiple sclerosis: what’s inside the toolbox? Neurotherapeutics 4(4):602–617
Adalsteinsson E, Langer-Gould A, Homer RJ et al (2003) Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24(10):1941–1945
Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294
PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet Neurol 352(9139):1498–1504
Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397
Chen JT, Kuhlmann T, Jansen GH et al (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36(4):1152–1158
Deloire MS, Salort E, Bonnet M et al (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(4):519–526
Vrenken H, Pouwels PJ, Ropele S et al (2007) Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 13(6):708–716
Laule C, Vavasour IM, Whittall KP et al (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250(8):924–931
Horakova D, Cox JL, Havrdova E et al (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 79(4):407–414
Davies GR, Ramio-Torrenta L, Hadjiprocopis A (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 75(7):998–1002
Oreja-Guevara C, Charil A, Caputo D et al (2006) Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63(5):736–440
Author information
Authors and Affiliations
Corresponding author
Additional information
J. Bellmann-Strobl, H. Stiepani and J. Wuerfel contributed equally to this work.
Rights and permissions
About this article
Cite this article
Bellmann-Strobl, J., Stiepani, H., Wuerfel, J. et al. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol 19, 2066–2074 (2009). https://doi.org/10.1007/s00330-009-1364-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-009-1364-z